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Hypertension in pediatric kidney transplant recipients contributes to long-term graft loss, yet treatment options—including
angiotensin-converting enzyme inhibitors—are poorly characterized in this vulnerable population. We conducted a multi-
center, open-label pharmacokinetic (PK) study of daily oral lisinopril in 22 children (ages 7–17 years) with stable kidney
transplant function. Standard noncompartmental PK analyses were performed at steady state. Effects on blood pressure
were examined in lisinopril-na€ıve patients (n513). Oral clearance declined in proportion to underlying kidney function; how-
ever, in patients with low estimated glomerular filtration rate (30–59 ml/min per 1.73m2), exposure (standardized to
0.1 mg/kg/day dose) was within the range reported previously in children without a kidney transplant. In lisinopril-na€ıve
patients, 85% and 77% had a6 mmHg reduction in systolic and diastolic blood pressure, respectively. Lisinopril was well
tolerated. Our study provides initial insight on lisinopril use in children with a kidney transplant, including starting dose
considerations.
The incidence of untreated or inadequately treated hyperten-
sion in pediatric kidney transplant recipients is nearly 60%, a
figure that has been steady over the last two decades.1 Uncon-
trolled hypertension, beginning within the first year posttrans-
plant, represents a modifiable risk factor that contributes to
long-term graft loss.1,2 The requirement for treatment with
antihypertensive medications at any time from 6 months to 3
years posttransplant is associated with graft dysfunction and a
lower glomerular filtration rate (GFR).3 Calcium channel
blockers are considered the preferred first-line agent in this cir-
cumstance,4 and they are the most commonly used drug class to
control posttransplant hypertension in children.5 However,
compared with calcium channel blockers, angiotensin-
converting enzyme inhibitors (ACEIs) may have additional
beneficial effects for prolonging allograft survival in kidney
transplant recipients by lowering intraglomerular hypertension
and reducing the activity of profibrotic molecules such as trans-
forming growth factor beta (TGF-b) and inflammatory media-
tors.6 Recent reports in adults document an increased use of
angiotensin-converting enzyme inhibitor (ACEI) in the 2-year
period after kidney transplantation between 1990 and 2002. By
the end of this period, 45% of patients were receiving these
agents, and their use was associated with a significantly higher
graft survival.7
Despite greater potential benefits, there is a reluctance to use
ACEIs in pediatric kidney transplant recipients who develop
hypertension because this class of drugs may compromise the
angiotensin II-dependent component of GFR in patients with a
single transplanted kidney. In addition, they may cause clinically
significant hyperkalemia.8 The low use of ACEI in pediatric kid-
ney transplant patients is noteworthy because these drugs lower
urinary protein excretion and are renoprotective in pediatric and
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adult patients with reduced kidney mass and/or diminished renal
function.9
Lisinopril, a long-acting ACEI, is approved by the US Food
and Drug Administration (FDA) for the treatment of adult and
pediatric patients with essential hypertension. Based on recovery
of the drug in the urine, the apparent extent of absorption of lis-
inopril is 25%, with large interpatient variability. In adults,
peak serum concentrations of lisinopril are seen 7 hours after
oral dosing.10 The disposition of lisinopril in children is similar
to adults, with peak concentrations observed within 6 hours after
dosing and the extent of drug absorption 28%.11,12 The drug is
not appreciably bound to plasma proteins and, thus, its disposi-
tion appears to be unaltered by low serum albumin levels.13 Lisin-
opril is not appreciably metabolized, and it is excreted largely
unchanged in the urine via glomerular filtration with no apparent
contribution via active tubular secretion.14 Impaired renal func-
tion decreases the elimination of lisinopril, but this only becomes
clinically relevant at a GFR below 30mL/min/1.73m2.
Compared to healthy children with essential hypertension, the
disposition of and response to antihypertensive medications may
be altered in pediatric patients with a renal transplant consequent
to the presence of a solitary kidney, potential alterations in renal
hemodynamics, renal effects of drugs used to prevent acute rejec-
tion, and extrarenal organ dysfunction secondary to chronic kid-
ney disease (CKD) prior to receipt of the kidney allograft. Thus,
it is important to understand if lisinopril disposition is altered in
pediatric patients who receive a renal transplant. Given the wide-
spread use of this drug in pediatrics, we conducted a clinical trial
to evaluate the pharmacokinetics (PK) and safety/tolerability
profile of lisinopril in children and adolescents with hypertension
after kidney transplantation. The impact of lisinopril on blood
pressure was also examined.
RESULTS
Patient characteristics
A total of 26 patients were enrolled and dosed (Figure 1). Three
patients did not complete the PK study day due to inability to
establish intravenous access (n5 1), withdrawal of consent
(n5 1), and an AE requiring study termination (n5 1). One
additional lisinopril-na€ıve patient completed PK sampling, but all
blood samples were lost after shipment to an off-site storage
facility in the wake of Hurricane Sandy. Therefore, a total of 22
patients were available for PK analysis (Table 1).
Twelve patients in the PK analysis population were enrolled in
the lisinopril-na€ıve group and received a drug dose according to
the study protocol. The highest dose enrolled in the lisinopril-
na€ıve group in the low eGFR group was 0.2mg/kg daily (one
patient) and in the high eGFR group was 0.4mg/kg (two
patients). Ten patients were receiving lisinopril as SoC. The
median dose in the lisinopril SoC group was 0.12mg/kg/day
(range, 0.03–0.21mg/kg). All patients in the lisinopril SoC group
received lisinopril once daily, except one who received lisinopril
twice daily. Patients were similar between the lisinopril-na€ıve and
lisinopril SoC groups in terms of age, weight, and eGFR (Supple-
mentary Table S1). There was a trend to a shorter time since
transplant in the lisinopril-na€ıve vs. lisinopril SoC patients
(3.16 3.0 years vs. 6.16 4.7 years; P5 0.08), although the dif-
ference between the mean values was not significant.
Concomitant antihypertensive medications in the PK analysis
population included amlodipine (n5 15), atenolol (n5 2), cloni-
dine (n5 2), isradipine (n5 2), and carvedilol (n5 1). Concomi-
tant immunosuppressive medications included mycophenolate
(n5 19), prednisone (n5 18), tacrolimus (n5 16), sirolimus
(n5 7), and azathioprine (n5 1). Antihypertensive and immuno-
suppressive medication doses remained stable during the study
period. No new oral concomitant medications were started during
the study period except for the following: odansetron (n5 1,
0.2mg/kg dose group), esomeprazole (n5 1, 0.2mg/kg dose
group), mycophenolate mofetil (n5 1, 0.1mg/kg dose group), and
vitamin D (n5 1, 0.4mg/kg dose). No patient in the study had
more than one transplant before enrollment.
Pharmacokinetics
The mean steady-state concentration–time profiles of lisinopril
once daily varied by dose level (Figure 2; Supplementary
Figure S1). Lisinopril PK exhibited dose proportionality with
area-under-the-concentration–time-curve over 24 hours (AUC0–
24) 2-fold higher in the 0.2mg/kg dose group compared with the
0.1mg/kg dose group (Table 2; geometric mean 640 vs. 298 ng/
ml*h respectively; P< 0.001). The geometric mean AUC0–24
across all patients dose-adjusted to a 0.1mg/kg dose was
328 ng*h/ml (coefficient of variation (CV) 60%). Dose-adjusted
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Lisinopril is approved to treat essential hypertension in
children and adolescents; however, little is known about
its use in pediatric kidney transplant recipients.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study sought to characterize lisinopril PK, short-
term safety, and preliminary efficacy in children with a
kidney transplant.
WHAT THIS STUDY ADDS TO OUR
KNOWLEDGE
 The PK of lisinopril in children with a kidney trans-
plant was similar to historical hypertensive children
without a kidney transplant. Lisinopril clearance
increased in proportion to kidney function. Lisinopril
was generally well tolerated and was accompanied by a
lowering of BP at approved pediatric doses in the study
population.
HOW THIS MIGHT CHANGE CLINICAL
PHARMACOLOGY AND THERAPEUTICS
 The current approved lisinopril starting dose of 0.07
mg/kg once daily (up to 5mg total) in children with
hypertension is likely appropriate based on PK consid-
erations for hypertensive children with a kidney trans-
plant and eGFR  30 ml/min per 1.73m2.
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AUC0–24, maximum concentration (Cmax), and concentration at
24 hours (C24) were not significantly different between the 0.1
and 0.2mg/kg dose groups (Table 3). Likewise, apparent oral
clearance was similar between the 0.1mg/kg and 0.2mg/kg dose
groups (geometric mean 17.9 vs. 18.6 L/h/70 kg, respectively;
P5 0.84). The extent of lisinopril absorption based on urinary
recovery (fe in urine), time of maximum concentration (Tmax),
and the apparent terminal elimination half-life (t1/2) were also
comparable across dose groups. Given the small sample size in
the high-dose group (n5 2), interpretation of the PK results in
this group is very limited.
The mean eGFR at the PK visit in the low and high GFR
groups was 44.46 9.6ml/min per 1.73m2 and 84.86 26.5ml/
min per 1.73m2, respectively. Lisinopril clearance was affected by
renal function. Apparent oral clearance was 11.9 (95% CI 8.4,
7.0) L/h/70 kg in the low GFR group vs. 24.0 (95% CI 19.4,
29.5) L/h/70 kg in the high GFR group (P< 0.001). Accord-
ingly, AUC0–24 dose-adjusted to 0.1mg/kg was 2-fold higher for
the low GFR group compared with the high GFR group (553 vs.
256 ngh /ml; P< 0.001). When plotting allometrically scaled
oral clearance (CL/F) vs. eGFR (Figure 3a), lisinopril clearance
increased in proportion to eGFR. In addition, the geometric
mean ratio of renal CL/eGFR was 0.84 (95% CI 0.71, 1.0),
which suggests, as expected, that renal CL of lisinopril is similar
to GFR. Consequently, there is a trend toward higher AUC0–24
per 0.1mg/kg as eGFR decreases (Figure 3b). For comparison,
the geometric mean AUC0–24 per 0.1mg/kg (5 437 ng*h/ml) in
a historical cohort of 16 children of similar age (age range, 12–15
years) was also included.15,16 The mean GFR in the historical
cohort was not reported; however, only one patient had a GFR
< 60ml/min per 1.73m2. The extent of lisinopril absorption
based on urinary recovery was not affected by eGFR (low eGFR
0.18 vs. high eGFR 0.19; P5 0.42). There was no indication of a
signal for a specific concomitant immunosuppressant affecting fe
in urine, and patients were generally on similar immunosuppres-
sant regimens.
Lasso regression analysis identified enrollment type (lisinopril-
na€ıve vs. SoC) as a significant predictor of clearance in addition
to eGFR. Apparent oral clearance was higher in treatment-na€ıve
patients compared with SoC patients (CL/F/70 kg 23.9 vs.
14.7 L/h/70 kg, respectively). No other significant predictors of
clearance were identified.
BP effects in lisinopril-na€ıve patients
Thirteen lisinopril-na€ıve patients had BP data available at base-
line and while on lisinopril treatment. Across all 13 patients, the
mean reduction in systolic BP from baseline at the lisinopril
trough timepoint was 9.06 6.9mmHg, with 11 (85%) having
had at least a 6-mmHg reduction. The mean reduction in dia-
stolic BP from baseline at the time of trough (Cmin) plasma lisin-
opril concentrations was 6.26 9.9mmHg, with 10 (77%) having
had at least a 6-mmHg reduction. Table 4 shows the change in
BP from baseline by dose group. At the lisinopril Cmin, change in
systolic BP from baseline in the 0.2mg/kg dose group estimated
from a linear mixed effects model was significant and clinically
relevant (–12 (95% CI 219.6, 24.4) mmHg). The reduction in
systolic BP was smaller in the 0.1mg/kg dose group and did not
reach statistical significance (–5.8 (95% CI 213.9, 2.2) mmHg).
Differences between dose groups were not statistically significant.
In the 12 patients with both PK and BP data available, no strong
relationships between change in systolic or diastolic BP and pre-
dose lisinopril concentration or AUC0–24 was observed
(R2  0.15 for all four analyses; Supplementary Figure S2).
Figure 1 CONSORT diagram.
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Changes in BP at other timepoints during the dosing interval on
the PK visit were not examined due to the confounding effect of
the iohexol administration with a lowering of BP (data not
shown).
Of patients with systolic BP or diastolic BP > 90th percentile
at enrollment, five (56%) of the nine patients achieved a systolic
BP < 90th percentile, and three (60%) of these five patients also
achieved a diastolic BP < 90th percentile at the lisinopril Cmin
timepoint. No patient required additional antihypertensive medi-
cations for BP control after lisinopril initiation.
Safety
Treatment-emergent AEs were reported in 11 of the 26 enrolled
patients (6/15 lisinopril-na€ıve and 5/11 lisinopril SoC). One seri-
ous AE was reported—an episode of gastroenteritis that required
hospitalization—but was considered unrelated to lisinopril. No
AEs related to the use of lisinopril were reported in SoC patients.
In lisinopril-na€ıve patients, AE rates by dose group were 2/6 in
0.1mg/kg/day, 2/6 in 2mg/kg/day, and 2/3 in the 0.4mg/kg/
day group, with one patient in each dose group reporting AEs
related to study drug. The following AEs deemed as potentially
related to study drug were reported: dizziness, nausea (two
patients), stomach ache, and eGFR decrease (see below).
One patient in the high-dose group was withdrawn from the
study per protocol after a > 20% decline in eGFR (99.7 to
78.4mL/min per 1.73m2) was detected at the interim visit while
the patient was receiving lisinopril 0.2 mg/kg per day. The eGFR
returned to the baseline level after lisinopril termination. No
other patient had a decrease in eGFR  16%. The Bland–
Altman plot to compare iohexol GFR (iGFR) and eGFR
calculated using the Schwartz bedside formula showed modest
correlation (concordance correlation coefficient5 0.69) but with
some variation across GFR averages of the two measures
(Supplementary Figure S3). The median change from baseline
in eGFR and serum potassium was 22 (range 221–13)mL/min
per 1.73m2 and 0.1 (range 21.3–0.7) mEq/L, respectively, in
lisinopril-na€ıve patients (Supplementary Table S2). During
follow-up, one lisinopril-na€ıve patient who continued on lisino-
pril (0.16mg/kg/day) experienced dizziness and nausea consid-
ered related to lisinopril. Lisinopril was subsequently
discontinued.
Table 1 Demographics of PK population patients by dose group
Parameter
Lisinopril dose group
All (n522)Low dose 0.1 mg/kg (n512) Middle dose 0.2 mg/kg (n58) High dose 0.4 mg/kg (n52)
Age (y) 14.962.3 1363 9.563.5 13.863.0
Weight (kg) 56.8619.4 50.2628.7 23.163 51.3623.8
Female 4 (42%) 2 (25%) 1 (50%) 7 (32%)
Race/ethnicity
White 7 (58%) 2 (25%) 2 (100%) 11 (50%)
Black 3 (25%) 4 (50%) 0 7 (32%)
American Indian or Alaska Native 0 (0) 1 (13%) 0 1 (5%)
Not reported 2 (17%) 1 (13%) 0 3 (14%)
Ethnicity Hispanic/Latino 2 (17%) 2 (25%) 0 4 (18%)
eGFR at baseline (ml/min per 1.73m2) 72.5625.7 (29.6, 111.2) 62616.7 (29.2, 79.8) 89.3644.4 (57.8, 120.6) 70.2624.4
eGFR at PK visit (ml/min per 1.73m2) 73.1630.7 (36.7, 139.0) 63.2618.4 (30.3, 86.0) 100.2656.6 (60.0, 140.2) 72.0629.4
Time since transplant (years) 4.864.7 4.963.4 0.960.4 4.564.1
Data are mean 6 SD (range) or counts (%); PK, pharmacokinetic; eGFR, estimated glomerular filtration rate calculated by modified Schwartz formula (50.4133 length
(cm)/serum creatinine (mg/dl)).
Figure 2 Mean lisinopril concentration vs. time after multiple dosing fol-
lowing once-daily dosing in patients who have received a kidney transplant.
Patients were stratified by dose group: low dose 5 0.1 mg/kg; middle
dose 5 0.2 mg/kg; and high dose 5 0.4 mg/kg. One patient received
twice-daily dosing and was not included.
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DISCUSSION
In this report we describe the PK, short-term safety/tolerability,
and preliminary efficacy data for use of lisinopril to treat hyper-
tension in pediatric kidney transplant recipients—an essential
step in demonstrating lisinopril as a safe and effective treatment
option for this population. The PK of lisinopril in patients with
a kidney transplant was comparable to a historical cohort of chil-
dren who did not have a kidney transplant and who were given
the drug for management of hypertension.11 In addition, lisino-
pril was generally well tolerated and was accompanied by a lower-
ing of BP at approved pediatric doses in nearly all patients with a
kidney transplant.
There are several additional key findings. First, the clearance of
lisinopril was not affected by age after scaling allometrically for
size across the age range studied. This is consistent with our cur-
rent understanding of renal maturation where, by 1 year of age,
GFR scaled for size is > 90% of adult levels.17–19 Second, lisino-
pril clearance was dose-proportional, and a doubling of the lisino-
pril dose can be expected to lead to a 2-fold higher systemic drug
exposure. Lastly, lisinopril clearance increased in proportion to
eGFR, a finding that corroborates prior knowledge with regard
to the renal excretion of the drug in adult patients.12,20 There-
fore, for a given lisinopril dose, systemic drug exposure in those
with renal impairment will be higher compared with those with
no renal impairment. The size of our study cohort and duration
of treatment were not sufficient to detect whether increased sys-
temic exposure to the drug in patients with renal compromise
had an effect on the AE profile.
The disposition of lisinopril in pediatric patients with a kidney
transplant was generally similar to that in those without a kidney
transplant.11,15,16 As expected, GFR was the major determinant
of drug clearance, and none of the factors associated with trans-
plantation, including concomitant administration of immuno-
suppressive agents, appeared to affect lisinopril clearance. The
time to maximum concentration after an oral dose and terminal
elimination half-life were also similar between the two popula-
tions (Tmax 5h vs. 6h and t1/2 9.5h vs. 8.8h in those with and
without a kidney transplant, respectively). However, AUC0–24
and Cmax dose adjusted to a 0.1mg/kg daily dose were lower in
patients with a kidney transplant compared to those without a
kidney transplant. The lower lisinopril exposure in patients with
a kidney transplant may be due, in part, to reduced oral
Table 2 Lisinopril pharmacokinetic parameters in patients with
a kidney transplant
PK parameter
Lisinopril dose
Low dose
0.1 mg/kg
(n512)
Middle dose
0.2 mg/kg
(n58)
High dose
0.4 mg/kg
(n52)
Dose (mg/kg/day)
Median 0.10 0.19 0.44
Range (0.03, 0.14) (0.17, 0.23) (0.40, 0.48)
AUC0-24(ngh /ml)
GeoMean 298 640 702
CV% (46.5) (28.6) (66.4)
CL/F per 70 kg
(L/h/70 kg)
GeoMean 17.9 18.6 32.8
CV% (61.2) (34.4) (54.1)
Cmax(ng/ml)
GeoMean 20.9 47.7 58.0
CV% (41.2) (25.1) (41.2)
Tmax(h)
Median 5.0 5.0 4.5
Range (4.0, 8.1) (4.0, 8.0) (4.0, 5.0)
C24(ng/ml)
GeoMean 5.4 11.2 13.1
CV% (51.7) (64.1) (212)
t1/2, terminal (h)
GeoMean 9.4 9.0 12.4
CV% (30.1) (46.1) (131)
fein urine
GeoMean 0.19 0.18 0.21
CV% (23.7) (14.8) (27.8)
Renal CL per 70 kg
(L/h/70 kg)
GeoMean 3.4 3.4 6.8
CV% (60.4) (46.0) (94.4)
PK, pharmacokinetic; AUC, area under the plasma concentration-time curve; CL/F,
oral clearance; Cmax, maximum observed concentration; Tmax, time of observed
maximal concentration; C24, concentration at 24 hours; t1/2, terminal half-life; fe,
fraction of dose excreted in urine during dosing interval; GeoMean, geometric
mean; CV%, percent coefficient of variation.
Table 3 Lisinopril PK parameters dose adjusted to a 0.1mg/kg
by dose group
PK parameter
Low dose
0.1 mg/kg
(n512)
Middle dose
0.2 mg/kg
(n58) P-value
AUC0-24per 0.1 mg/kg
GeoMean 365 333 0.71
95% CI (243, 549) (265, 419)
Cmaxper 0.1 mg/kg
GeoMean 26.9 24.8 0.70
95% CI (18.4, 39.5) (20.9, 29.5)
C24per 0.1 mg/kg
GeoMean 6.9 5.8 0.61
95% CI (4.1, 11.7) (3.5, 9.7)
PK, pharmacokinetic; AUC, area under the plasma concentration-time curve; Geo-
Mean, geometric mean; CI, confidence interval; Cmax, maximum observed concen-
tration; C24, concentration at 24 hours.
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bioavailability of lisinopril in the kidney transplant population.
This is suggested by the lower fraction of drug excreted in urine,
which was 0.19 in the current study vs. 0.27 in pediatric patients
without a kidney transplant.20 The reason for this reduced
absorption may relate to the large number of concomitant medi-
cations (including immunosuppressive medications) resulting in
potential drug–drug interactions that affect lisinopril absorption.
Alternatively, the underlying disease state in pediatric patients
with a kidney transplant may alter intestinal function, which, in
turn, might be expected to potentially affect either the rate and/
or extent of absorption.
When considering the effect of renal impairment on lisinopril
clearance in pediatric patients with a kidney transplant, the
changes in exposure are likely not clinically relevant at typical lis-
inopril starting doses in those with eGFR  30ml/min per
1.73m2. For example, the AUC0–24 dose adjusted to a 0.1mg/kg
daily dose in pediatric patients with a kidney transplant and
moderate renal impairment was on average 553 ng*h/ml, which
is comparable to values reported in those without a kidney trans-
plant receiving lisinopril (AUC0–24 dose adjusted to a 0.1mg/kg
daily dose 437 ng*h/ml) and in adults receiving 5mg daily
(AUC0–24 450 ng*h/ml).
15,16,21 Therefore, no dose adjustment is
likely to be needed in pediatric patients with a kidney transplant
who have moderate renal impairment (eGFR 30–59ml/min per
1.73m2), consistent with current dose recommendations in chil-
dren and adults without a kidney transplant in whom the starting
dose is not adjusted until eGFR < 30ml/min per 1.73m2.20
The current study provides insight into the effect of lisinopril
on BP in pediatric patients with a kidney transplant. In the 13
lisinopril-na€ıve patients with clinical BP data before and after lis-
inopril treatment, more than 75% had a reduction of  6
mmHg in systolic and/or diastolic pressure. No apparent expo-
sure–response relationship was evident in our study cohort. Our
inability to detect such a relationship may be attributed to the
small sample size of our cohort and the fact that only two
patients were enrolled in the highest-dose group. Nonetheless,
the BP response at 0.1 and 0.2mg/kg per day was clinically rele-
vant, as it corroborates the available anecdotal evidence that lis-
inopril at these doses is effective in normalizing BP in this
population, as has been the experience when using it to treat
hypertension in children without a kidney transplant.22 Use of
the highest dose (0.4 mg/kg) may not be necessary to achieve a
clinically relevant reduction in blood pressure and may increase
the risk of AEs. Whether nighttime dosing to improve nocturnal
BP control would achieve better overall BP levels and greater
preservation of kidney function in pediatric kidney transplant
recipients will require further study, including ambulatory blood
Figure 3 Impact of eGFR on (a) oral clearance allometrically scaled to a 70 kg adult and (b) AUC0–24 dose adjusted to 0.1 mg/kg/day. The geometric
mean AUC0–24 dose adjusted to 0.1 mg/kg in historical hypertensive children is shown for comparison.
Table 4 Change in clinic blood pressure by dose group in
lisinopril-na€ıve patients
Change in BP from
baseline
Baseline
BP (mmHg)
Lisinopril
BP (mmHg) Mean 95% CI
Trough (predose)
Systolic
0.1 mg/kg (n56) 121.263.9 115.367.6 25.8 (213.9, 2.2)
0.2 mg/kg (n55) 129.666.7 117.666.5 212 (219.6,24.4)
0.4 mg/kg (n52) 124.569.2 113.566.4 211 N/A
Diastolic
0.1 mg/kg (n56) 75.7612.8 69.266.6 26.5 (221, 8)
0.2 mg/kg (n55) 73.867.5 68.2611.8 25.6 (215, 3.8)
0.4 mg/kg (n52) 76.5616.3 69.5614.8 27 N/A
Data are mean 6 SD. BP, blood pressure; CI, confidence interval.
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pressure monitoring (ABPM) assessment of morning vs. evening
dosing.23
Lisinopril was well tolerated at the doses used in this study.
Only one patient had a decline in GFR that required discontinua-
tion of the study drug. In this patient, the 22% decline in eGFR
was based on a 0.1mg/dL increase in the serum creatinine con-
centration from 0.3 to 0.4mg/dL. In the interests of safety, we
applied a very strict 20% limit to the allowable decline in GFR fol-
lowing initiation of lisinopril. Generally, up to a 30% decline in
GFR is considered an acceptable change if an ACEI is used as a
renoprotective agent in patients with CKD. Our data are encour-
aging, but close monitoring of GFR will be necessary in future tri-
als of lisinopril in this patient population. We relied upon eGFR
to assess kidney function in this study because it was more feasible
for the serial determinations required by the protocol. Iohexol
clearance measurements confirmed that the estimated GFRs were
reasonably representative of the underlying kidney function in the
transplant population. More work is needed to clarify the rela-
tionship between eGFR and iGFR to determine the optimal
method to assess the effect of long-term use of ACEI in kidney
function in renal transplant recipients. This is underscored by
studies suggesting that specific formulas to estimate GFR are
required in pediatric patients who have a kidney allograft.24 No
cases of hyperkalemia occurred in our cohort of pediatric renal
transplant recipients who were treated with an ACEI.
Despite the relatively small sample size of our study cohort
and the narrow range of daily doses, both the PK and pharma-
codynamic (PD) results observed corroborate and expand on
what is known regarding the disposition and action of this drug
in pediatric patients. Our decision to include SoC patients, in
retrospect, was important in expanding our study cohort so as
to enable us to obtain meaningful, generalizable PK data
obtained in a “target” population (i.e., those in whom the drug
was being used to treat hypertension). The clinically relevant
reduction in BP at the 0.1 and 0.2 mg/kg/day doses suggests
that the higher dose may not be necessary to achieve BP control.
However, we did not evaluate the basal activity of the renin
angiotensin system in these patients, which may have been
informative in understanding variation in BP response. In addi-
tion, long-term treatment studies will be required to determine
if intensified BP control using an ACEI as part of the treatment
regimen will achieve renoprotection in pediatric patients with a
kidney transplant, as was the case in the ESCAPE trial of chil-
dren with CKD who maintained native kidney function.25,26
The same caveat applies to children < 6 years of age, as con-
trolled clinical trials characterizing the PK and PD of lisinopril
in younger children remain to be performed. It should be noted,
however, that if lisinopril is used during the first year of life at a
time where the expected normal GFR is considerably lower
than adult values, an increase in systemic drug exposure and its
attendant PD effects can be expected. Finally, trials involving
long-term lisinopril exposure will be required to demonstrate
the sustained safety and efficacy of ACEIs such as lisinopril in
the treatment of pediatric kidney transplant recipients. The
results from the current study can be used to inform such future
clinical trials.
METHODS
Study design
This was a prospective, open-label, multicenter safety and PK study of
lisinopril in pediatric kidney transplant recipients. It was conducted
across seven sites within the Eunice Kennedy Shriver National Institute
of Child Health and Human Development (NICHD) Pediatric Trials
Network (PTN). The study protocol was approved by the Institutional
Review Board at each participating site. Informed parental consent and
patient assent, where appropriate, were obtained for each patient.
Patients
Patients were kidney transplant recipients 7–17 years of age. Two eligible
populations were enrolled. The first population comprised lisinopril-
na€ıve patients who were required to have systolic blood pressure (BP)
 75th percentile for age, sex, and height; an estimated GFR (eGFR)
 30ml/min per 1.73m2; stable allograft function (< 20% change in
serum creatinine during the prior 30 days); and stable immunosuppres-
sive regimen (< 10% dose change during the prior 14 days). The second
population enrolled included lisinopril standard of care (SoC) patients
for whom lisinopril was already prescribed as part of an antihypertensive
regimen. Because recruitment of lisinopril-na€ıve patients was slower than
projected, the lisinopril SoC patient population was added midstudy,
and the systolic BP criterion was expanded from the original study crite-
rion of > 90th percentile in the na€ıve cohort. Patients in either enroll-
ment population were excluded if they had: 1) received an ACEI other
than lisinopril, an angiotensin receptor blocker (ARB), or renin antago-
nist within 30 days prior to enrollment; 2) known allergy or hypersensi-
tivity to ACEI, iohexol, or iodine; 3) stage 2 hypertension; 4) serum
potassium > 6mEq/L; 5) ongoing plasmapheresis treatment; 6) history
of angioedema; or 7) positive pregnancy test.
Lisinopril dose and formulation
Lisinopril-na€ıve patients received oral lisinopril once daily at doses that
approximated 0.1mg/kg, 0.2mg/kg, or 0.4mg/kg until the PK visit. The
PK visit occurred 10–16 days after the start of lisinopril treatment.
Those who received 0.4mg/kg daily were first started on 0.2mg/kg daily.
They returned after 3–7 days for an interim visit, and, if no adverse
events (hyperkalemia or decline in eGFR  20%) were experienced, then
the dose was increased to 0.4mg/kg daily and continued until the PK
visit. Patients were assigned to a dose level based on eGFR in a dose-
escalation strategy. Patients were enrolled in either a low eGFR (30–
59ml/min per 1.73m2) or high eGFR ( 60ml/min per 1.73m2) group.
Within each eGFR group, the planned enrollment strategy was for the
first three patients to receive lisinopril 0.1mg/kg daily, the next four
patients to receive 0.2mg/kg daily, and the final four patients to receive
0.4mg/kg daily.
Lisinopril SoC patients received the dose of lisinopril already pre-
scribed as part of their ongoing management. The PK visit occurred 11–
41 days after enrollment. For analysis, patients were assigned to a dose-
level group (0.1, 0.2, or 0.4mg/kg) and eGFR group (low or high) as
defined above.
Lisinopril was given orally as a tablet (2.5mg, 5mg, 10mg, or 20mg
dose strength). For lisinopril-na€ıve patients, the dose prescribed was
within 2.5mg (the lowest dose strength available in tablet formulation)
of the assigned weight-based dose level. Patients were instructed to take
the medication at the same time and in the same manner each day. Med-
ication adherence was assessed by use of a medication diary. In addition,
on each of the 2 days prior to the PK visit, the patient was contacted via
phone by a study nurse and instructed to record the date and time of
study medication administration. On the day of the PK visit, patients
fasted for 2 hours prior to study drug administration.
Pharmacokinetic sampling
Venous blood samples (1 mL) for quantification of lisinopril were col-
lected predose and at 1, 2, 4, 5, 8, 12, and 24 hours post-lisinopril
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dose. The blood samples were collected in ethylenediaminetetraacetic
acid (EDTA)-K2 tubes and centrifuged within 30 minutes at 1,500–
2,000g for 10 minutes at 4C. Plasma was removed and stored within
8 hours at <2 70C until analysis, which did not exceed 18 months
for any sample. In addition, a 24-hour quantitative urine collection
was performed for drug level measurement following lisinopril dosing.
The 24-hour urine collection was started after the patient voided just
prior to receiving the dose of lisinopril. All urine excreted was pooled
over the following time intervals: 0–4, 4–8, 8–12, and 12–24 hours.
Urine was kept refrigerated at 4C during a collection time period.
Samples were then gently mixed by inversion, the volume recorded,
and two 8-ml aliquots were stored at <2 70C until analysis. On the
PK study day, iohexol clearance was concurrently performed to evalu-
ate the correlation between the modified Schwartz formula and
iohexol clearance-based determination of GFR. A 4–timepoint blood
sampling procedure over 5 hours (0, 2, 4, and 5 hours) was used in
accordance with procedures established in the CkiD cohort study.27
The iohexol determinations were performed in the laboratory of
George J. Schwartz, MD, University of Rochester Medical Center,
NY.
Blood pressure measurement
BP was measured at the start of study (prior to first dose of lisinopril in
lisinopril-na€ıve patients) and at preselected study time points on the PK
study day (predose, 10 minutes postiohexol infusion, and 4, 8, 12, and
24 hours post lisinopril dose). At each timepoint, 2–3 BP readings in the
sitting position were obtained using the appropriate cuff size, and the
values were averaged.
Safety
All patients were monitored for adverse events (AEs) throughout study
enrollment and were followed for at least 30 days following the PK study
day. Only treatment-emergent events are summarized. All new events
that occurred or preexisting conditions that worsened in frequency or
intensity were recorded as AEs. Laboratory tests were performed at the
baseline and PK visits.
Analytical methods
The concentration of lisinopril in plasma and urine was measured using
high-pressure liquid chromatography–tandem mass spectrometry
(HPLC-MS/MS) by OpAns (Durham, NC). Methods were validated
according to FDA guidance. For plasma, the lower limit of quantifica-
tion was 0.5 ng/ml, and the calibration curve ranged from 0.5–500 ng/
mL. The within-run and between-run coefficients of variation ranged
from 2.3–10.9% and 6.1–9.6%, respectively, across the concentrations
spanning the range of linearity. For urine, the lower limit of quantifica-
tion was 50 ng/ml, and the calibration curve ranged from 50–15,000 ng/
mL. The within-run and between-run coefficients of variation ranged
from 2.4–6.1% and 3.6–6.3%, respectively, across the concentrations
spanning the range of linearity.
Pharmacokinetic analyses
Steady-state PK parameters for lisinopril were estimated from plasma
and urine concentration data via noncompartmental analysis using Phoe-
nix WinNonlin (v. 6.3; Certara, St. Louis, MO). The Cmax and Tmax
were obtained directly from the observed data. Clast was defined as the
last observed quantifiable concentration during the dosage interval and
was equivalent to the C24 for patients on once-daily dosing and the con-
centration at 12 hours (C12) for the single patient on twice-daily dosing.
The AUC0–24 was calculated using the linear/logarithmic trapezoidal
method. AUC0–24 was calculated as AUC0–123 2 for the one patient
on twice-daily dosing. To allow direct comparisons across dose groups,
Cmax, C24, and AUC0–24 were also dose-adjusted to a 0.1mg/kg daily
dose based on patient dose and weight. CL/F was calculated as daily
dose/AUC0–24. CL/F was then scaled for size to a 70 kg adult (CL/F/
70 kg) using an allometric exponent of 0.75.17,18 The terminal rate
constant (kz) was determined by linear regression analysis of the terminal
portion of the log plasma concentration–time curve. The t1/2 was calcu-
lated as ln 2/kz. It is worth noting that due to the PK sampling strategy
and slower absorption rate of lisinopril, the robustness of the estimate of
t1/2 for patients may have been limited. Renal clearance (renal CL) was
calculated as the total amount of lisinopril excreted in urine over 24
hours divided by the AUC0–24, except for the one patient who was tak-
ing twice-daily dosing for whom renal CL was calculated as the amount
of lisinopril excreted in urine over 12 hours divided by AUC0–12. Renal
CL was normalized toml/min per 1.73m2 to allow direct comparison to
eGFR. The fraction of lisinopril dose excreted in urine over a dosing
interval (fe in urine) was calculated from the cumulative measured uri-
nary recovery over the dosing interval divided by the dose.
Statistical analyses
Summary demographic data are presented as count (%) or mean 6 stand-
ard deviation (SD). Summary PK data are presented as the geometric
mean (GeoMean) and CV%, except daily dose and Tmax, which are pre-
sented as the median and range. PK parameters were compared by 0.1 vs.
0.2mg/kg/day dose groups and low vs. high eGFR groups. The 0.4mg/
kg/day dose group was not compared due to the limited sample size
(n5 2). Differences between groups were compared using Student’s t-test
or the Mann–Whitney U-test for continuous data and Fisher’s exact test
for categorical data. Log transformation of all PK parameters except Tmax
was performed prior to statistical analysis. The impact of potentially clini-
cally relevant covariates on log-transformed CL/F/70 kg was examined by
a Lasso regression analysis using 5-fold cross-validation with the predicted
residual sums of squares (PRESS) selection criterion in SAS v. 9.3 (Cary,
NC). The following covariates were considered: age, sex, time since trans-
plant, tacrolimus use, sirolimus use, prednisone use, mycophenolate use,
enrollment type (lisinopril-na€ıve vs. SoC), daily lisinopril dose, eGFR,
urine protein/creatinine ratio, and microalbuminuria.
To examine the effect of lisinopril on BP, change in sitting systolic
and diastolic BP from baseline (i.e., prior to lisinopril initiation) was cal-
culated in lisinopril-na€ıve patients using the measured BP immediately
before lisinopril administration (i.e., trough BP) on the PK visit. Mean
BP change was estimated separately for the 0.1 and 0.2mg/kg/day dose
groups using 95% confidence intervals (CI) based on the t-distribution.
For safety assessments, an intent-to-treat approach was used. In addition,
the highest grade clinical laboratory abnormality while on lisinopril was
reported.
All tests of significance were 2-sided, and the significance limit
accepted for all statistical analyses was a 5 0.05. Adjustments for multi-
plicity were not performed for these exploratory, descriptive compari-
sons. All statistical analyses were performed in SAS v. 9.3.
CONCLUSION
The PK of lisinopril in pediatric patients with a kidney trans-
plant was consistent with previous data in those without a kidney
transplant, and lisinopril clearance was predictably related to
underlying kidney function. The drug was well tolerated and
associated with a clinically meaningful reduction in BP. The cur-
rently labeled lisinopril starting dose of 0.07mg/kg once daily
(up to 5mg total) in patients with hypertension is likely appro-
priate based on PK considerations for hypertensive children with
a kidney transplant and eGFR  30ml/min per 1.73m2.
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